(Cefepime + Taniborbactam hydrochloride) is a small molecule commercialized by Everest Medicines, with a leading Phase III program in Pyuria. According to Globaldata, it is involved in 8 clinical trials, of which 7 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for (Cefepime + Taniborbactam hydrochloride) is expected to reach an annual total of $28 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Cefepime + Taniborbactam hydrochloride) Overview
Fixed dose combination of cefepime and taniborbactam hydrochloride (VNRX-5133) is under development for the treatment of multi-drug resistant (MDR) gram-negative infections such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa infections, complicated urinary tract infections (cUTI) including acute pyelonephritis, pyuria, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It is administered intravenously as a powder for solution . The therapeutic candidate acts by targeting beta lactamase and penicillin binding protein 2.
See Also:
It was also under development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) including acute pyelonephritis.
Everest Medicines Overview
Everest Medicines is a biopharmaceutical company. It develops and commercializes pharmaceutical products and vaccines for the treatment of cancer, autoimmune, cardiorenal and infectious diseases. The company’s pipeline products include NEFECON, an oral release formulation that targets mucosal B-cells to treat renal diseases; and EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor to treat renal diseases. Its pipeline also includes Taniborbactam, a novel injectable beta-lactamase inhibitor to treat infectious diseases; and SPR206 for the treatment of MDR gram-negative bacterial infections, among others. Its product includes Xerava, a synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram positive, gram negative and anaerobic pathogens. The company works in collaboration with Immunomedics, Novartis, Arena Pharmaceuticals, and others. Everest Medicines is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY12.8 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY0.1 million in FY2021. The operating loss of the company was CNY256.8 million in FY2022, compared to an operating loss of CNY1,026.3 million in FY2021. The net loss of the company was CNY247.3 million in FY2022, compared to a net loss of CNY1,008.7 million in FY2021.
For a complete picture of (Cefepime + Taniborbactam hydrochloride)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
